Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia

Cancer

Volumn 117, Issue 12, 2011, Pages 2735-2746

  Ding, Ning ^a   Yamashita, Uki ^a   Matsuoka, Hidetada ^a   Sugiura, Tsutomu ^a   Tsukada, Junichi ^b   Noguchi, Junko ^a   Yoshida, Yasuhiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

apoptosis; cucurbitacin D; NF B; proteasome inhibition; T cell leukemia

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CUCURBITACIN; CUCURBITACIN D; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LEUKEMIA; UBIQUITINATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; MICE, SCID; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; TRITERPENES; UBIQUITINATION;

EID: 79958786749     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25711     Document Type: Article

References (43)

1. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004; 5: 664-672. (Pubitemid 40267851)
2. Jayaprakasam B, Seeram NP, Nair MG., Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett. 2003; 189: 11-16. (Pubitemid 35351514)
3. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX,. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep. 2005; 22: 386-399.
4. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM., Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003; 63: 1270-1279. (Pubitemid 36348705)
5. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM,. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 2005; 24: 3236-3245. (Pubitemid 40695105)
6. Takahashi N, Yoshida Y, Sugiura T, Matsuno K, Fujino A, Yamashita U., Cucurbitacin D isolated from Trichosanthes kirilowii induces apoptosis in human hepatocellular carcinoma cells in vitro. Int Immunopharmacol. 2009; 9: 508-513.
7. Porter AG, Janicke RU., Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6: 99-104. (Pubitemid 29082297)
8. Lee TL, Yeh J, Friedman J, et al. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer. 2008; 122: 1987-1998. (Pubitemid 351441187)
9. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007; 109: 2293-2302. (Pubitemid 46425866)
10. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 1999; 93: 2360-2368. (Pubitemid 29153640)
11. Karin M, Lin A., NF-kappaB at the crossroads of life and death. Nat Immunol. 2002; 3: 221-227.
12. Mori N, Yamada Y, Ikeda S, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002; 100: 1828-1834. (Pubitemid 34925163)
13. Richardson PG, Mitsiades C, Hideshima T, Anderson KC., Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005; 4: 290-296. (Pubitemid 41365336)
14. Adams J., The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4: 349-360. (Pubitemid 38579481)
15. Chen Z, Ricker JL, Malhotra PS, et al. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther. 2008; 7: 1949-1960.
16. Nasr R, El-Sabban ME, Karam JA, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005; 24: 419-430. (Pubitemid 40188590)
17. Voorhees PM, Orlowski RZ., The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006; 46: 189-213. (Pubitemid 43271188)
18. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK., Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001; 1: 194-202. (Pubitemid 33741894)
19. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S., The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 2003; 102: 3765-3774. (Pubitemid 37409399)
20. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007; 110: 267-277. (Pubitemid 47026844)
21. Liu J, Yoshida Y, Yamashita U., DNA-binding activity of NF-kappaB and phosphorylation of p65 are induced by N-acetylcysteine through phosphatidylinositol (PI) 3-kinase. Mol Immunol. 2008; 45: 3984-3989.
22. Yoshida Y, Kumar A, Koyama Y, et al. Interleukin 1 activates STAT3/nuclear factor-kappaB cross-talk via a unique TRAF6- and p65-dependent mechanism. J Biol Chem. 2004; 279: 1768-1776. (Pubitemid 38084444)
23. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M., Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia. 2004; 18: 1357-1363. (Pubitemid 39136745)
24. Kang MH, Reynolds CP., Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009; 15: 1126-1132.
25. Tamatani M, Che YH, Matsuzaki H, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem. 1999; 274: 8531-8538. (Pubitemid 29164643)
26. Jonas E., BCL-xL regulates synaptic plasticity. Mol Interv. 2006; 6: 208-222. (Pubitemid 44455203)
27. Nielsen M, Kaestel CG, Eriksen KW, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999; 13: 735-738. (Pubitemid 29243625)
28. Catz SD, Johnson JL., Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001; 20: 7342-7351. (Pubitemid 33078205)
29. Okudaira T, Tomita M, Uchihara JN, et al. NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway. Mol Cancer Ther. 2006; 5: 704-712.
30. Ishikawa C, Tafuku S, Kadekaru T, et al. Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int J Cancer. 2008; 123: 2702-2712.
31. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61: 3071-3076. (Pubitemid 32691956)
32. Yamamoto Y, Gaynor RB., IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci. 2004; 29: 72-79. (Pubitemid 38186577)
33. Zheng B, Georgakis GV, Li Y, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res. 2004; 10: 3207-3215. (Pubitemid 38619702)
34. Almond JB, Cohen GM., The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002; 16: 433-443. (Pubitemid 34449723)
35. Hirano Y, Hendil KB, Yashiroda H, et al. A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. Nature. 2005; 437: 1381-1385. (Pubitemid 41568686)
36. Rosenzweig R, Glickman MH., Forging a proteasome alpha-ring with dedicated proteasome chaperones. Nat Struct Mol Biol. 2008; 15: 218-220. (Pubitemid 351654052)
37. Konopa J, Matuszkiewicz A, Hrabowska M, Onoszka K., Cucurbitacines, cytotoxic and antitumor substances from Bryonia alba L. Part II: Biological studies. Arzneimittelforschung. 1974; 24: 1741-1743.
38. Konopa J, Zielinski J, Matuszkiewicz A., Cucurbitacins, cytotoxic and antitumor substances from Bryonia alba L. I: Isolation and identification. Arzneimittelforschung. 1974; 24: 1554-1557.
39. Park CS, Lim H, Han KJ, et al. Inhibition of nitric oxide generation by 23,24-dihydrocucurbitacin D in mouse peritoneal macrophages. J Pharmacol Exp Ther. 2004; 309: 705-710. (Pubitemid 38542626)
40. Pei XY, Dai Y, Grant S., Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004; 10: 3839-3852. (Pubitemid 38697620)
41. Yin L, Laevsky G, Giardina C., Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem. 2001; 276: 44641-44646.
42. Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S., Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008; 14: 549-558. (Pubitemid 351226125)
43. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006; 108: 3441-3449.